Pharma-Bio Serv, Inc. announced that revenues for the three and six months ended April 30, 2023 were approximately $4.6 and $8.8 million, respectively, a decrease of approximately $0.4 and $1.2 million, respectively, when compared to the same periods last year.
DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2023 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and six months ended April 30, 2023 were approximately $4.6 and $8.8 million, respectively, a decrease of approximately $0.4 and $1.2 million, respectively, when compared to the same periods last year. Gross profit for the three and six months ended April 30, 2023 increased by 5.0 and 4.8 percentage points, respectively, when compared to the same periods last year.
Net income for the three and six months ended April 30, 2023 was approximately $0.4 and $0.8 million, respectively, an increase of approximately $0.2 and $0.3 million, when compared to the same periods last year.
“We are pleased to report an increase in our net income and the significant gross profit percentage improvement we achieved for the six months ended April 30, 2023. We plan to continue our strategy of maximizing our resources in the most profitable markets and grow our presence in those locations,” stated Mr. Sanchez, Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv’s core business is FDA and international agencies regulatory compliance consulting related services. The Company’s global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv’s management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv’s actual results or performance to differ materially from the forward-looking statements include those set forth in the “Risk Factors” section of Pharma-Bio Serv’s Annual Report on Form 10-K for the year ended October 31, 2022, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv, Inc.
View source version on accesswire.com:
https://www.accesswire.com/761375/Pharma-Bio-Serv-Announces-Results-for-the-Three-and-Six-Months-Ended-April-30-2023
